On Tuesday, Cullinan Therapeutics Inc (NASDAQ: CGEM) was 3.37% up from the session before settling in for the closing price of $11.87. A 52-week range for CGEM has been $9.24 – $30.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. When this article was written, the company’s average yearly earnings per share was at 17.66%. With a float of $37.15 million, this company’s outstanding shares have now reached $58.14 million.
Let’s look at the performance matrix of the company that is accounted for 85 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cullinan Therapeutics Inc (CGEM) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cullinan Therapeutics Inc stocks. The insider ownership of Cullinan Therapeutics Inc is 36.20%, while institutional ownership is 77.32%. The most recent insider transaction that took place on Dec 18 ’24, was worth 53,547. In this transaction Chief Scientific Officer of this company sold 4,693 shares at a rate of $11.41, taking the stock ownership to the 99,760 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Medical Officer sold 4,632 for $11.41, making the entire transaction worth $52,851. This insider now owns 114,059 shares in total.
Cullinan Therapeutics Inc (CGEM) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 17.66% per share during the next fiscal year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
You can see what Cullinan Therapeutics Inc (CGEM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 24.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.17 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Cullinan Therapeutics Inc (NASDAQ: CGEM) saw its 5-day average volume 0.62 million, a negative change from its year-to-date volume of 0.64 million. As of the previous 9 days, the stock’s Stochastic %D was 67.70%. Additionally, its Average True Range was 0.77.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 19.37%, which indicates a significant decrease from 57.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.23% in the past 14 days, which was higher than the 54.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.18, while its 200-day Moving Average is $17.81. Nevertheless, the first resistance level for the watch stands at $12.54 in the near term. At $12.81, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.25. If the price goes on to break the first support level at $11.84, it is likely to go to the next support level at $11.40. Assuming the price breaks the second support level, the third support level stands at $11.13.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
There are 58,228K outstanding shares of the company, which has a market capitalization of 714.45 million. As of now, sales total 0 K while income totals -153,160 K. Its latest quarter income was 0 K while its last quarter net income were -40,560 K.
